Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 0.0% | 26.6% | 24.8% | 69.0% | 105.1% | 56.9% | 180.9% | 138.7% | 109.1% | (339.6%) | (94.9%) | 187.7% | 81.0% | 72.4% | 35.2% |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month Return on Equity (ROE) is 79.3%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Return on Equity (ROE) for AbbVie Inc. have been 64.8% over the past three years, and 50.1% over the past five years.
As of today, AbbVie Inc.'s Return on Equity (ROE) is 79.3%, which is higher than industry median of 18.5%. It indicates that AbbVie Inc.'s Return on Equity (ROE) is Good.